SEPTInvestingStart Free

RADX 6-K: Insider sale planned

Radiopharm Theranostics

Filed with the SEC on · accession 0001213900-26-118421

RADX filed a 6-K (foreign company report) with the SEC on Nov 12, 2026. How foreign companies listed in the US report news and events — like an 8-K for them.

Summary of the filing

Radiopharm Theranostics filed a Form 6-K attaching four Change of Director's Interest Notices published to the Australian Securities Exchange, disclosing changes in directors' interests in the company's securities.

For details, click here →How to read a 6-K →

Key details

RegistrantRadiopharm Theranostics Limited
Company secretaryAmritha Sushil

✦ Ask GOAX AI about this filing — what it means for RADX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for RADX?

Click here

Frequently asked questions

What did RADX file with the SEC on Nov 12, 2026?

RADX filed a 6-K (Insider sale planned). Radiopharm Theranostics filed a Form 6-K attaching four Change of Director's Interest Notices published to the Australian Securities Exchange, disclosing changes in directors' interests in the company's securities.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other RADX SEC filings

Get alerts when RADX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
RADX overviewRADX analysisRADX newsLatest SEC filings